scholarly journals Long-term Follow-up of Pure Ductal Carcinoma in situ after Breast-Conserving Surgery

2019 ◽  
Vol 7 (2) ◽  
pp. 73-80
Author(s):  
Keong Won Yun ◽  
Jisun Kim ◽  
Jong Won Lee ◽  
Sae Byul Lee ◽  
Hee Jeong Kim ◽  
...  
Keyword(s):  
Ductal Carcinoma In Situ ◽  
Carcinoma In Situ ◽  
Ductal Carcinoma ◽  
Breast Conserving Surgery ◽  
Long Term Follow Up

scholarly journals Long term follow-up of women with ductal carcinoma in situ treated with breast-conserving surgery

Cancer ◽  
1999 ◽  
Vol 86 (9) ◽  
pp. 1757-1767 ◽  
Author(s):  
Kimberly J. Van Zee ◽  
Laura Liberman ◽  
Billur Samli ◽  
Katherine N. Tran ◽  
Beryl McCormick ◽  
...  
Keyword(s):  
Ductal Carcinoma In Situ ◽  
Carcinoma In Situ ◽  
Ductal Carcinoma ◽  
Breast Conserving Surgery ◽  
Long Term Follow Up

The natural history of low-grade ductal carcinoma in situ of the breast in women treated by biopsy only revealed over 30 years of long-term follow-up

Cancer ◽  
2005 ◽  
Vol 103 (12) ◽  
pp. 2481-2484 ◽  
Author(s):  
Melinda E. Sanders ◽  
Peggy A. Schuyler ◽  
William D. Dupont ◽  
David L. Page
Keyword(s):  
Natural History ◽  
Ductal Carcinoma In Situ ◽  
Carcinoma In Situ ◽  
Ductal Carcinoma ◽  
Low Grade ◽  
Long Term Follow Up ◽  
History Of

Predicting relapse in ductal carcinoma in situ patients: an analysis of biologic markers with long-term follow-up

2007 ◽  
Vol 194 (4) ◽  
pp. 504-506 ◽  
Author(s):  
Tina J. Hieken ◽  
John Cheregi ◽  
Miguel Farolan ◽  
Joan Kim ◽  
Josè M. Velasco
Keyword(s):  
Ductal Carcinoma In Situ ◽  
Carcinoma In Situ ◽  
Ductal Carcinoma ◽  
Biologic Markers ◽  
Long Term Follow Up

scholarly journals Significance of HER-2/neu Overexpression in Ductal Carcinoma In Situ: A Clinicopathologic Study With Long-Term Follow-up

2012 ◽  
Vol 138 (suppl 2) ◽  
pp. A152-A152
Author(s):  
Thomas Stockl ◽  
Ashraf Khan ◽  
Richard Horner ◽  
Zeina Al-Mansour ◽  
Ediz Cosar ◽  
...  
Keyword(s):  
Ductal Carcinoma In Situ ◽  
Carcinoma In Situ ◽  
Ductal Carcinoma ◽  
Clinicopathologic Study ◽  
Long Term Follow Up ◽  
Her 2

Breast-Conserving Treatment With or Without Radiotherapy in Ductal Carcinoma-In-Situ: Ten-Year Results of European Organisation for Research and Treatment of Cancer Randomized Phase III Trial 10853—A Study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group

2006 ◽  
Vol 24 (21) ◽  
pp. 3381-3387 ◽  
Author(s):  
Nina Bijker ◽  
Philip Meijnen ◽  
Johannes L. Peterse ◽  
Jan Bogaerts ◽  
Irène Van Hoorebeeck ◽  
...  
Keyword(s):  
Ductal Carcinoma In Situ ◽  
Carcinoma In Situ ◽  
Ductal Carcinoma ◽  
Phase Iii ◽  
Breast Conserving Treatment ◽  
European Organisation ◽  
Radiotherapy Group ◽  
Long Term Follow Up

Purpose The European Organisation for Research and Treatment of Cancer conducted a randomized trial investigating the role of radiotherapy (RT) after local excision (LE) of ductal carcinoma-in-situ (DCIS) of the breast. We analyzed the efficacy of RT with 10 years follow-up on both the overall risk of local recurrence (LR) and related to clinical, histologic, and treatment factors. Patients and Methods After complete LE, women with DCIS were randomly assigned to no further treatment or RT (50 Gy). One thousand ten women with mostly (71%) mammographically detected DCIS were included. The median follow-up was 10.5 years. Results The 10-year LR-free rate was 74% in the group treated with LE alone compared with 85% in the women treated by LE plus RT (log-rank P < .0001; hazard ratio [HR] = 0.53). The risk of DCIS and invasive LR was reduced by 48% (P = .0011) and 42% (P = .0065) respectively. Both groups had similar low risks of metastases and death. At multivariate analysis, factors significantly associated with an increased LR risk were young age (≤ 40 years; HR = 1.89), symptomatic detection (HR = 1.55), intermediately or poorly differentiated DCIS (as opposed to well-differentiated DCIS; HR = 1.85 and HR = 1.61 respectively), cribriform or solid growth pattern (as opposed to clinging/micropapillary subtypes; HR = 2.39 and HR = 2.25 respectively), doubtful margins (HR = 1.84), and treatment by LE alone (HR = 1.82). The effect of RT was homogeneous across all assessed risk factors. Conclusion With long-term follow-up, RT after LE for DCIS continued to reduce the risk of LR, with a 47% reduction at 10 years. All patient subgroups benefited from RT.

scholarly journals Adherence to Long-Term Surveillance Mammography Among Women With Ductal Carcinoma In Situ Treated With Breast-Conserving Surgery

2009 ◽  
Vol 27 (19) ◽  
pp. 3211-3216 ◽  
Author(s):  
Larissa Nekhlyudov ◽  
Laurel A. Habel ◽  
Ninah S. Achacoso ◽  
Inkyung Jung ◽  
Reina Haque ◽  
...  
Keyword(s):  
Ductal Carcinoma In Situ ◽  
Carcinoma In Situ ◽  
Ductal Carcinoma ◽  
Breast Conserving Surgery ◽  
First Year ◽  
Adjuvant Radiation ◽  
Obese Women ◽  
Surveillance Mammography

Purpose Breast-conserving surgery (BCS) is an effective treatment for ductal carcinoma in situ (DCIS) but women who undergo BCS remain at risk for recurrences. Whether mammographic surveillance after BCS occurs and by whom is not known. Methods We reviewed medical records of women diagnosed with DCIS between 1990 and 2001 and treated with BCS. Using descriptive statistics, generalized estimating, and logistic regression modeling, we examined the rates and predictors of surveillance mammography over a 10-year period after BCS. Results The cohort included 3,037 women observed for a median of 4.8 years (range, 0.5 to 15.7). Of the 2,676 women observed for at least 1 year after BCS, most (79%) had at least one surveillance mammogram during the first year of follow-up; 69% in year 5 and 61% in year 10. Among those observed for 5 years, surveillance mammograms were more likely among women age 60 to 69 years (odds ratio [OR], 1.72; 95% CI, 1.26 to 2.34), users of menopausal hormone therapy at diagnosis (OR, 1.26; 95% CI, 1.01 to 1.57) as well as those treated with adjuvant radiation (OR, 1.28; 95% CI, 1.08 to 1.53) and adjuvant radiation with tamoxifen (OR, 1.61; 95% CI, 1.13 to 2.30). Surveillance mammograms were less likely among obese women (OR, 0.70; 95% CI, 0.56 to 0.86). The findings were similar among women observed for 10 years. Only 34% and 15% of women observed for 5 and 10 years, respectively, had a surveillance mammogram during each year of follow-up. Conclusion Surveillance mammography after BCS among insured women with DCIS often did not occur yearly and declined over time after treatment. Patients and providers must remain vigilant about surveillance after BCS.

Sign in / Sign up

Export Citation Format

Share Document